Saltar al contenido
PivotalWire
Viernes 2 oct 2026SEC · NASDAQ biomédico

Calendario›MDWD›Long Term Follow up of Scars Formation and Quality of Life Assessment Study

Long Term Follow up of Scars Formation and Quality of Life Assessment Study

Ensayo de MediWound Ltd. en Scars Formation · Quality of Life (del registro, en inglés).

Fase
no aplica
Estado
Completado
Participantes
148
previstos
Centros
1
Fin del objetivo primario
nov 2011
fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en jun 2011.

Qué mide

1. Scar assessment of target wounds that have been treated by Debrase or SOC during MW2004-11-02 using Modified Vancouver Scar Scale (MVSS) (Approximately 2 years after wound closure) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroIn previous study (MW2004-011-02), patients with burn wounds had their damaged skin removed by either standard of care treatment or by Debrase Gel Dressing (DGD), which is composed of enzymes that dissolve the damaged skin selectively (DGD removes only the damaged skin and not other parts of the skin). The burn wound, like any other wound, heals by the formation of scar at the injured site in order to replace the destroyed tissues. Scarring is not a static process, but rather a dynamic one, changing over time, especially during the first 24 months post-injury. Scars and patients' quality of life from two treatment arms (DGD and SOC) will be compared in order to evaluate the long term influence of damaged skin removal and wound care techniques on scar formation and maturation.

Más ensayos de MDWD

EnsayoFaseEstadoLectura de resultados
EscharEx 5%Fase 1/2Reclutando pacientesmay 2022 (prevista, ya pasada: sin actualizar en el registro)
EscharEx · VALUEFase 3Reclutando pacientesdic 2026 (prevista)
EscharEx · VLUFase 2Aún sin reclutardic 2027 (prevista)
EX-03Fase 2Aún sin reclutarago 2028 (prevista)
EscharExFase 2Completadomay 2022 (real)
EscharExFase 2Completadodic 2021 (real)

Todos los de MDWD, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT01350700), actualizada en oct 2017.